Sydney, Australia 5 August 2026 Highlights Preliminary assessment of the 8 GBq 67Cu-SAR-bisPSMA dose cohorts Nineteen participants from the SECuRE trial (NCT04868604)1 were included in this assessment of the safety and efficacy of the 8 GBq 67Cu-SAR-bisPSMA dose level. This includes 3 participants from cohort 2 of the Dose Escalation phase and 16 participants from…
Sydney, Australia 16 July 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that Ms Allison Rossiter has joined Clarity’s Board of Directors as an independent Non-Executive Director. Allison Rossiter is an experienced…
Sydney, Australia 29 June 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of data on 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for presentation at the European Association of Nuclear Medicine (EANM) Annual Congress…
Sydney, Australia 26 June 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has welcomed its 100th team member to the organisation. Our focus on people is at the core of…
Sydney, Australia 14 May 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has received a Research and Development (R&D) Tax Incentive refund of $9,759,467, as part of the Australian Federal…
Sydney, Australia 14 April 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for 64Cu-SAR-bisPSMA with Nucleus Radiopharma, an innovative contract development and manufacturing organisation (CDMO)…
Sydney, Australia 9 April 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, announces that its Executive Director, Dr Colin Biggin, is stepping down from the Board. He will continue in his role as Chief Operating Officer…
Sydney, Australia 31 March 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results from the Co-PSMA (NCT06907641)1 investigator-initiated trial (IIT) are now published in European Urology2, the official journal of…
Sydney, Australia 25 March 2026 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics. The agreement relates to Theragenics’ 134,000 square foot…
Sydney, Australia 17 March 2026 Highlights Oral presentation on key results from the Co-PSMA (NCT06907641)1 Investigator-Initiated Trial (IIT) was delivered by Prof Louise Emmett (St Vincent’s Hospital Sydney) at the European Association of Urology (EAU) Congress 2026 on the 16th of March 2026 in London, UK2. Co-PSMA trial data has also been accepted for publication…